After GLP-1, what’s next for weight loss?
alongside weight reduction, but it improves the overall lean-to-fat mass ratio. Bimagrumab will need to better that; its sponsors also hope it will avoid the weight rebound associated with incretin therapies.
Larger, longer trials are required to determine the safety and efficacy of these approaches. Obesity drug development is littered with failures. Uncoupling agent 2,4-dinitrophenol , used for weight loss until the mid-twentieth century, caused fever, hyperthermia and death. Sanofi’s appetite-curbing rimonabant, a cannabinoid receptor antagonist, was withdrawn from the European market in 2008, two years after launch, owing to severe mood disorders.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Genentech to close plant near Sacramento after Bay Area layoffsThe move comes after the biotechnology giant recently announced it was laying off more than 200 employees in South San Francisco.
Weiterlesen »
Multi-omics resources for targeted agronomic improvement of pigmented rice - Nature FoodGenome assemblies, genetic variations, and metabolome and metal ion profiles were generated for diverse pigmented Asian rice varieties. An early maturing, shorter-stature black rice variety was created using CRISPR–Cas9-mediated genome editing, providing insights for improving Asian pigmented rice.
Weiterlesen »
George Saunders on the Nature of Mind“Fiction is often concerned with that fundamental human question: What is that person over there thinking, anyway?” George Saunders discusses “Thursday,” his short story from this week’s issue of the magazine.
Weiterlesen »
Nature Conservancy of Canada releases plan to protect Prairie grasslandsPlans are in the works to raise $500 million by 2030 to conserve more than 5,000 sq. km of grassland in Alberta, Saskatchewan and Manitoba.
Weiterlesen »
Researchers and regulators plan for a future without lab animals - Nature MedicineThe US Food and Drug Administration has reduced requirements for preclinical animal testing, leading to a surge of interest in organoids, tissue chips and in silico testing.
Weiterlesen »